Story perspectives

Bristol-Myers Squibb Surpasses Earnings, Targets $5B Alzheimer’s Drug

1/16/2025

29 7

Summary

Story summary

Meyer Handelman Co. decreased its Bristol-Myers Squibb stake by 1.9%, now holding 553,168 shares valued at $31.3 million.
Analysts continue to recommend a "Hold" rating, with several firms raising price targets, indicating potential growth.
Bristol-Myers Squibb's new drug, Cobenfy, aims at Alzheimer's conditions, with anticipated sales of $5 billion by 2030.
The company reported Q3 earnings of $1.80 per share, surpassing estimates, and plans to raise its dividend to $0.62 per share.

1 of 1

Story summary

Meyer Handelman Co. decreased its Bristol-Myers Squibb stake by 1.9%, now holding 553,168 shares valued at $31.3 million.
Analysts continue to recommend a "Hold" rating, with several firms raising price targets, indicating potential growth.
Bristol-Myers Squibb's new drug, Cobenfy, aims at Alzheimer's conditions, with anticipated sales of $5 billion by 2030.
The company reported Q3 earnings of $1.80 per share, surpassing estimates, and plans to raise its dividend to $0.62 per share.